FFA
INO icon

Farther Finance Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Farther Finance Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122 Buy
111
+75
+208% +$89 ﹤0.01% 5773
2026
Q1 		$63 Buy
36
+20
+125% +$33 ﹤0.01% 5556
2025
Q4 		$28 Hold
16
– – ﹤0.01% 5380
2025
Q3 		$37 Hold
16
– – ﹤0.01% 4883
2025
Q2 		$33 Hold
16
– – ﹤0.01% 4403
2025
Q1 		$24 Sell
16
-30
-65% -$60 ﹤0.01% 4184
2024
Q4 		$84 Buy
46
+10
+28% +$44 ﹤0.01% 3808
2024
Q3 		$208 Sell
36
-813
-96% -$6.71K ﹤0.01% 3640
2024
Q2 		$7.31K Sell
849
-1
-0.1% -$11 ﹤0.01% 2206
2024
Q1 		$11.1K Sell
850
-21
-2% -$181 ﹤0.01% 1716
2023
Q4 		$5.33K Hold
871
– – ﹤0.01% 1940
2023
Q3 		$4.07K Buy
871
+21
+2% +$116 ﹤0.01% 1584
2023
Q2 		$4.56K Hold
850
– – ﹤0.01% 1463
2023
Q1 		$8.37K Hold
850
– – ﹤0.01% 1171
2022
Q4 		$15.9K Buy
+850
New +$19.3K 0.01% 801

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Farther Finance Advisors's INO Position: Q2 2026 in Review

Farther Finance Advisors increased its Inovio Pharmaceuticals (INO) stake by 208% in Q2 2026, buying an estimated $89 and bringing the position to 111 shares worth $122. The position accounts for ﹤0.01% of the portfolio, ranked #5773.

Farther Finance Advisors first reported a position in INO in Q4 2022 and has held it in 15 quarters since. The position peaked at $15.9K in Q4 2022. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Farther Finance Advisors held 111 shares of Inovio Pharmaceuticals worth $122 as of Q2 2026.
  • Farther Finance Advisors bought 75 Inovio Pharmaceuticals shares in Q2 2026, an estimated $89.
  • Inovio Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5773 holding.
  • Farther Finance Advisors first reported a position in Inovio Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Inovio Pharmaceuticals position peaked at $15.9K in Q4 2022.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.